Lyra Therapeutics Inc
NASDAQ:LYRA
Lyra Therapeutics Inc
NASDAQ:LYRA
Price:
0.3622 USD
1.8%
Market Closed
Updated:
May 16, 2024
Lyra Therapeutics Inc
Cash from Financing Activities
|
Lyra Therapeutics Inc
Cash from Financing Activities Peer Comparison
Comparables:
JNJ
BMY
PFE
MRK
LLY
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Lyra Therapeutics Inc
NASDAQ:LYRA
|
Cash from Financing Activities
$65.7m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
18%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Cash from Financing Activities
-$21.4B
|
CAGR 3-Years
-46%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-10%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash from Financing Activities
$8.3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Pfizer Inc
NYSE:PFE
|
Cash from Financing Activities
$26.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Merck & Co Inc
NYSE:MRK
|
Cash from Financing Activities
-$5.6B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
14%
|
CAGR 10-Years
-7%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash from Financing Activities
$2.8B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Lyra Therapeutics Inc's Cash from Financing Activities?
Cash from Financing Activities
65.7m
USD
65.7m
USD
Based on the financial report for Dec 31, 2023, Lyra Therapeutics Inc's Cash from Financing Activities amounts to 65.7m USD.
What is Lyra Therapeutics Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
18%
18%
Over the last year, the Cash from Financing Activities growth was -32%. The average annual Cash from Financing Activities growth rates for Lyra Therapeutics Inc have been -9% over the past three years , 18% over the past five years .
You don't have any saved screeners yet
